In Phase C, individuals will acquire ABBV-744 and oral navitoclax. In Phase D, individuals will obtain ABBV-744 and ruxolitinib. Participants will receive treatment right until illness progression or even the contributors are not able to tolerate the study drugs. There may be better treatment stress for contributors Within this trial https://richardk666yku9.wikibuysell.com/user